Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life
Survival outcomes were not affected by history of TKI treatment. Nilotinib is favorable for HRQoL but increases the risk of serious CVEs in patients with vascular risk factors.
Authors
- James Moon (ORCID: https://orcid.org/0000-0001-8071-1491)
- Yunji Lee (ORCID: https://orcid.org/0000-0002-7124-8690)
- Hee Jeong Cho (ORCID: https://orcid.org/0000-0001-8300-8179)
- Dong Won Baek (ORCID: https://orcid.org/0000-0003-4446-1549)
- Sang Kyun Sohn (ORCID: https://orcid.org/0000-0002-1874-3959)
- Juhyung Kim
- Young eun Jang
Institutions
- Kyungpook National University Hospital (KR)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1159/000542562
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77